Amgen Is Spending Disproportionately More (Based On Market Cap), Than Its Peers... On Lobbying.

As is Pfizer -- yet Pfizer, unlike most of the rest of big cap PhRMA members, is proceeding apace -- while the others. . . seem to be taking more of a "wait him out" approach to Trump, and his wildly dysfunctional Congress.

It seems the big ones are waiting to see what comes of November mid-terms -- and are not putting much stock in 45's bluster about attacking prices. We shall see (most recent Q2 numbers here).

[But don't take my word for it -- go take a look for yourselves -- you may search by any company name, there.]

In any event, this time we will feature just what Amgen spent on (ignoring all others):

. . . .Biosimilars, no specific bill; Prescription drug value issues, no specific bill; S. 469 Affordable and Safe Prescription Drug Importation Act; H.R. 1245 Affordable and Safe Prescription Drug Importation Act; S.Con.Res.3: A concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2017 and setting forth the appropriate budgetary levels for fiscal years 2018-2026 (importation, non-interference); 340B Protecting Access for the Underserved and Safety-Net Entities (340B PAUSE Act). . . .

S. 2042 Reducing Drug Waste Act of 2017; H.R. 6142 Reducing Drug Wastage Act of 2018; FDA issues, no specific bill; S. 3158 Labor, Health and Human Services Appropriations Act (Senate Report 115-289). . . .

Medicare Part B (Average Sales Price); Medicare Part D issues ; Coding and reimbursement for oncology drugs/biologics/biosimilars; 340B Protecting Access for the Underserved and Safety-Net Entities; S 2312 "Helping Ensure Low-Income Patients have Access to Care and Treatment" (HELP Act); S 2453 "Ensuring the Value of the 340B Program Act of 2018"; H.R. 5598 "340B Optimization Act"; Senate Report 115-289 to accompany S.3158 Appropriations bill for the Department of Labor, Health and Human Services, and Education, and related agencies for the fiscal year 2019; H.R. 6142 Reducing Drug Waste Act. . . .

International tax issues, including: H.R.1: An Act to provide for reconciliation pursuant to titles II and V of the concurrent resolution on the budget for fiscal year 2018; Puerto Rico Tax Incentives . . .

S. 974 CREATES Act of 2017; S. 124 Preserve Access to Affordable Generics Act; Issues related to drug patents and exclusivities (no bill). . . .

Now you know. Onward -- to a Centenary Birthday celebration, web-wide, for Ms. Katherine Johnson, in the morning!



नमस्ते